Schizophrenia

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

December 2025 psychiatry updates: Teva files TEV-‘749 for schizophrenia, lumateperone boosts MDD outcomes, AGA tied to mental health, and a look back at 2025 advances.

An audio recap of the top 5 stories in healthcare news from the week of 12/28-1/3.

In 2025, psychiatry saw major FDA approvals, novel treatments, and pivotal clinical updates that are transforming care for depression, ADHD, schizophrenia, and anxiety.

Teva submitted an NDA on olanzapine extended-release injectable suspension (TEV-‘749) for adult schizophrenia to the FDA.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

A 30-week trial found weekly semaglutide reduced HbA1c while improving physical quality of life in patients on antipsychotics.

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

Long-acting injectables improve outcomes in schizophrenia, yet remain underutilized, highlighting the need for earlier, proactive conversations in care.

Panelists discuss how current standard treatments primarily address positive symptoms through D2 receptor blockade medications and cognitive behavioral therapy but often provide only partial efficacy while potentially worsening negative and cognitive symptoms that most impact daily functioning.

Panelists discuss how schizophrenia affects 3.5 million Americans through 3 distinct symptom domains––positive symptoms (hallucinations), negative symptoms (social isolation, reduced functioning), and cognitive symptoms ––rather than just the commonly perceived “hearing voices.”

Cutler told HCPLive it was surprising that a new survey on subcutaneous TEV- ‘749 revealed 50% and 45.5% of nurses and physicians, respectively, preferred intramuscular injections.